Quentin McCubbin
Keine laufenden Positionen mehr
Vermögen: 44 893 $ am 30.04.2024
Profil
Quentin McCubbin worked as Vice President-Pharmaceutical Sciences at Takeda Pharmaceutical Co., Ltd.
from 2012 to 2019.
He then worked as Chief Manufacturing Officer at Frequency Therapeutics, Inc. before becoming Head-Technical Operations at Cerevel Therapeutics LLC from 2019 to 2021.
Dr. McCubbin received his undergraduate and doctorate degrees from Monash University in 1992 and 1995, respectively.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,01% | 26.01.2023 | 767 ( 0,01% ) | 44 893 $ | 30.04.2024 |
Ehemalige bekannte Positionen von Quentin McCubbin
| Unternehmen | Position | Ende |
|---|---|---|
Cerevel Therapeutics LLC
 Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2021 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01.01.2019 |
| KORRO BIO, INC. | Corporate Officer/Principal | - |
Ausbildung von Quentin McCubbin
| Monash University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Frequency Therapeutics, Inc.
 Frequency Therapeutics, Inc. BiotechnologyHealth Technology Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore function. The firm is also involved in creating and commercializing therapeutics to potentially transform the lives of individuals by repairing or reversing damage done to cells, tissue, and organs. The company was founded by Robert S. Langer, David L. Lucchino, Christopher R. Loosey, and Will J. McLean on November 13, 2014 and is headquartered in Lexington, MA. | Health Technology |
Cerevel Therapeutics LLC
Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA. | Health Technology |
